September 8, 2021 -- Mission Bio has improved its Tapestri platform to expand its accessibility and utility in hematologic oncology (heme-onc) research.
The updates allow researchers to apply single-cell analysis to a wider range of projects due to new ready-to-use panels, Tapestri single-cell DNA published panels, and a lowered input threshold. Researchers now can access single-cell insights from as few as 20,000 cells while conserving samples.
BioLegend's expanded TotalSeq D antibodies catalog has also been added to Tapestri. The addition enables researchers to start with a predesigned heme-onc panel (or customize one to fit the needs of a specific project) and connect genomic data to a broader array of phenotypes, according to the firm.
Mission Bio is hosting a virtual launch event of its platform on September 21, 2021, at 8 a.m. Pacific time.
Copyright © 2021 scienceboard.net